tradingkey.logo

Trinity Biotech PLC

TRIB
0.800USD
+0.092+13.06%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
15.41MValor de mercado
PerdaP/L TTM

Trinity Biotech PLC

0.800
+0.092+13.06%

Mais detalhes de Trinity Biotech PLC Empresa

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Informações de Trinity Biotech PLC

Código da empresaTRIB
Nome da EmpresaTrinity Biotech PLC
Data de listagemOct 21, 1992
CEOGillard (John)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 21
EndereçoIda Business Park, Bray, Co Wicklow
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal18
Telefone01135312955111
Sitehttps://www.trinitybiotech.com/
Código da empresaTRIB
Data de listagemOct 21, 1992
CEOGillard (John)

Executivos da empresa Trinity Biotech PLC

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
Por RegiãoUSD
Nome
Receita
Proporção
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

Distribuição de ações

Atualizado em: dom, 1 de fev
Atualizado em: dom, 1 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Outro
29.87%
Investidores
Investidores
Proporção
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Outro
29.87%
Tipos de investidores
Investidores
Proporção
Corporation
60.60%
Hedge Fund
6.69%
Investment Advisor
5.47%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.46%
Outro
26.08%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
52
2.76M
62.28%
+305.43K
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
MiCo IVD Holdings, LLC
2.24M
60.6%
+1.79M
+400.00%
Dec 08, 2025
Renaissance Technologies LLC
171.36K
4.64%
+159.97K
+1404.10%
Sep 30, 2025
Hunter Associates Investment Management LLC
487.11K
13.19%
+399.53K
+456.18%
Sep 30, 2025
Citadel Advisors LLC
39.38K
1.07%
+39.38K
--
Sep 30, 2025
Two Sigma Investments, LP
36.23K
0.98%
+33.22K
+1101.76%
Sep 30, 2025
CAPTRUST Financial Advisors
27.25K
0.74%
+27.25K
--
Sep 30, 2025
Raymond James & Associates, Inc.
20.32K
0.55%
+15.25K
+300.77%
Sep 30, 2025
Williams & Novak Wealth Management, LLC
12.00K
0.32%
+7.60K
+172.73%
Sep 30, 2025
Becker Capital Management, Inc.
18.00K
0.49%
+14.40K
+400.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
16.64K
0.45%
+13.31K
+400.06%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Data
Data ex-dividendo
Tipo
Proporção
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI